For instance, CD123/CLL-1 tandem CAR-Ts demonstrate significantly increased cytotoxicity and cytokine release to AML cells, expressing both CD123 and CLL-1 antigens in comparison to single-target CAR-T therapy [66]. Here, CLEC12A is linked to acute myeloid leukemia.